摘要
目的集中探讨SEPT9基因甲基化对于直结肠癌早期诊断中的临床应用意义。方法随机选取2015年3～12月因患结直肠癌于笔者医院普外科进行手术治疗的患者100例，从术中切取的癌灶、其癌旁组织和术前粪便样本中提取DNA，应用多重置换扩增（MDA）结合巢式甲基化特异性PCR扩增技术（nMPS）检测患者术前粪便样本中SEPT9基因的甲基化水平，同时比较粪便同癌灶组织中SEPT9基因甲基化在诊断结直肠癌中的敏感度及特异性。结果针对100例患者的癌灶组织的SEPT9基因的分析的过程中，基因甲基化的发生率为84．0％；在针对癌旁组织的SEPT9基因的过程中，基因甲基化的发生率为8．0％。患者癌灶及癌旁组织SEPT9基因甲基化发生率的比较差异有统计学意义（P〈0．01）；临床分期为Ⅰ、Ⅱ期的结直肠癌患者，采用SEPT9基因甲基化诊断的准确率为87．5％；临床分期为Ⅲ、Ⅳ期的结直肠癌患者，采用SEPT9基因甲基化诊断的准确率为80．0％。针对不同的临床分期，采用SEPT9基因甲基化诊断结直肠癌的准确率差异无统计学意义（P〉0．05）。结论因粪便中SEPT9基因甲基化检测在结直肠癌患者中的特异性和敏感度较高，可在临床中应用于直结肠癌的早期诊断。
Objective To investigate the diagnosis of colorectal cancer by analysis of SEPT9 methylation in stool DNA. Methods The stool SEPT9 gene methylation were detected by multiple displacement amplification/nested methylation specific PCR, MDA -nMSP in 100 colorectal cancer tissues,para - cancer tissues and stool DNA. The sensitivity and specificity of SEPT9 methylation marker in colorec- tal cancer diagnosis were analyzed. Results Among 100 colorectal cancers,SEPT9 gene methylation was found in 84.0% of cancer tis- sues and 8.0% of para - cancer tissues respectively. The sensitivity and specificity of SEPT9 for diagnosis of colorectal cancer were 84.0% and 92.0% , respectively,and the stool SEPT9 had similar sensitivity as cancer tissues in diagnosis of colorectal cancer. There were no any differences for incidence of SEPT9 methylation among different clinical stages. Conclusion The abnormal methylation of SEPT9 happened frequently in colorectal cancer. Hypermethylaion of SEPT9 gene mehylation in stool DNA can be used as a candidate of tumor marker for early diagnosis of colorectal cancer.
出处
《医学研究杂志》
2016年第8期142-144,152,共4页
Journal of Medical Research
